Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 9/2020

01-06-2020

SF-6D health state utilities for lifestyle, sociodemographic and clinical characteristics of a large international cohort of people with multiple sclerosis

Auteurs: Julie A. Campbell, George A. Jelinek, Tracey J. Weiland, Nupur Nag, Sandra L. Neate, Andrew J. Palmer, Brendan Mulhern, Alysha De Livera, Steve Simpson-Yap

Gepubliceerd in: Quality of Life Research | Uitgave 9/2020

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Background

While many studies have examined the impacts of multiple sclerosis (MS) on health-related quality of life (HRQoL), none have used the SF-6D multi-attribute utility instrument in a large international cohort (> 2000 subjects) of people with MS.

Objectives

To derive SF-6D health state utilities (HSUs) for participants of the HOLISM (Health Outcomes and Lifestyle In a Sample of people with Multiple Sclerosis) international cohort and to describe the distribution and determinants thereof.

Methods

HSUs were generated using the SF-6D for participants with sufficient SF-36 data [n = 2185/2466 (88.6%)]. Mean HSUs for sociodemographic, clinical and modifiable lifestyle factors (including diet, physical activity, supplement use) were evaluated. Determinants of HSU were then evaluated by linear regression, adjusted for age, sex, MS type, disability, fatigue, and prescription antidepressant use.

Results

Mean HSU for the sample was 0.67 (SD = 0.13) and diminished with increasing MS-related disability, robust to adjustment, supporting the SF-6D’s discriminatory power in people with MS. Severe disability and clinically significant fatigue were each associated with 11% lower HSU (95% CI = − 0.13, − 0.10 and − 0.12, − 0.10), and depression risk with 10%-lower HSU (95% CI = − 0.11, − 0.08). Employment, higher socioeconomic and married/partnered statuses, larger social-network size, greater physical activity, and vitamin D and omega-3 supplement use were associated with significantly higher HSU, and overweight/obese BMI and tobacco smoking with lower HSU. Age, sex, and education were not associated.

Conclusion

Modifiable lifestyle factors including healthy diet, increased physical activity and supplement use were associated with higher HRQOL among people with MS. The SF-6D instrument revealed significant discriminatory power in this international cohort of people with MS.
vorige artikel Development of algorithms to estimate EQ-5D and derive health utilities from WHOQOL-HIV Bref: a mapping study
volgende artikel Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
Compston, A., McDonald, I., Noseworthy, J. H., et al. (2005). McAlpine's multiple sclerosis (4th ed.). Oxford: Churchill Livingston.
2.
Hadgkiss, E. J., Jelinek, G. A., Weiland, T. J., et al. (2015). The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis. Nutritional Neuroscience., 18, 125–136.PubMedPubMedCentralCrossRef
3.
Wingerchuk, D. M. (2011). Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking. Mount Sinai Journal of Medicine, 78, 221–230.PubMedCrossRef
4.
Canto, E., & Oksenberg, J. R. (2018). Multiple sclerosis genetics. Multiple Sclerosis, 24, 75–79.PubMedCrossRef
5.
Tao, C., Simpson, S., Jr., van der Mei, I., et al. (2016). Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 87, 1343–1349.PubMedCrossRef
6.
Palmer, A. J., Colman, S., O'Leary, B., et al. (2013). The economic impact of multiple sclerosis in Australia in 2010. Multiple Sclerosis, 19, 1640–1646.PubMedCrossRef
7.
8.
Browne, P., Chandraratna, D., Angood, C., et al. (2014). Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity. Neurology., 83, 1022–1024.PubMedPubMedCentralCrossRef
9.
10.
11.
12.
13.
Richardson, J., Iezzi, A., Khan, M. A., et al. (2016). Measuring the sensitivity and construct validity of 6 utility instruments in 7 disease areas. Medical Decision Making, 36, 147–159.PubMedCrossRef
14.
Campbell, J. A., Palmer, A. J., Venn, A., et al. (2016). A head-to-head comparison of the EQ-5D-5L and AQoL-8D multi-attribute utility instruments in patients who have previously undergone bariatric surgery. Patient, 9, 311–322.PubMedCrossRef
15.
Brazier, J., Ratcliffe, J., Saloman, J., et al. (2017). Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press.
16.
Fayers, P. M., & Machin, D. (2013). Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. New York: Wiley.
17.
Drummond, M. F., Sculpher, M. J., Claxton, K., et al. (2015). Methods for the economic evaluation of health care programmes (4th ed.). Oxford: Oxford University Press.
18.
Clarke, P. M., Hayes, A. J., Glasziou, P. G., et al. (2009). Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Medical Care, 47, 61–68.PubMedCrossRef
19.
Skinner, E. H., Denehy, L., Warrillow, S., et al. (2013). Comparison of the measurement properties of the AQoL and SF-6D in critical illness. Critical Care and Resuscitation, 15, 205.PubMed
20.
Claflin, S. B., van der Mei, I. A. F., & Taylor, B. V. (2018). Complementary and alternative treatments of multiple sclerosis: A review of the evidence from 2001 to 2016. The Journal of Neurology, Neurosurgery, and Psychiatry, 89, 34–41.PubMedCrossRef
21.
Hadgkiss, E. J., Jelinek, G. A., Weiland, T. J., et al. (2013). Methodology of an international study of people with multiple sclerosis recruited through Web 2.0 platforms: Demographics, lifestyle, and disease characteristics. Neurology Research International, 2013, 580596.PubMedPubMedCentral
22.
Jelinek, G. A., De Livera, A. M., Marck, C. H., et al. (2016). Lifestyle, medication and socio-demographic determinants of mental and physical health-related quality of life in people with multiple sclerosis. BMC Neurology, 16, 235.PubMedPubMedCentralCrossRef
23.
Marck, C. H., Hadgkiss, E. J., Weiland, T. J., et al. (2014). Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: A large international survey. BMC Neurology, 14, 143.PubMedPubMedCentralCrossRef
24.
Jelinek, G. A., Hadgkiss, E. J., Weiland, T. J., et al. (2013). Association of fish consumption and Omega 3 supplementation with quality of life, disability and disease activity in an international cohort of people with multiple sclerosis. International Journal of Neuroscience, 123, 792–800.PubMedCrossRef
25.
Weiland, T. J., Hadgkiss, E. J., Jelinek, G. A., et al. (2014). The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis. Journal of the Neurological Sciences, 336, 211–219.PubMedCrossRef
26.
Fisk, J. D., Brown, M. G., Sketris, I. S., et al. (2005). A comparison of health utility measures for the evaluation of multiple sclerosis treatments. The Journal of Neurology, Neurosurgery, and Psychiatry, 76, 58–63.PubMedCrossRef
27.
Hohol, M. J., Orav, E. J., & Weiner, H. L. (1995). Disease steps in multiple sclerosis: A simple approach to evaluate disease progression. Neurology, 45, 251–255.PubMedCrossRef
28.
Kister, I., Chamot, E., Salter, A. R., et al. (2013). Disability in multiple sclerosis: A reference for patients and clinicians. Neurology, 80, 1018–1024.PubMedPubMedCentralCrossRef
29.
Krupp, L. B., LaRocca, N. G., Muir-Nash, J., et al. (1989). The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology, 46, 1121–1122.PubMedCrossRef
30.
Kroenke, K., Spitzer, R. L., & Williams, J. B. (2003). The Patient Health Questionnaire-2: Validity of a two-item depression screener. Medical Care, 41(1), 1284–1292.PubMedCrossRef
31.
McKellar, S., Horsley, P., Chambers, R., Bauer, J. D., Vendersee, P., Clarke, C., et al. (2008). Development of the diet habits questionnaire for use in cardiac rehabilitation. Australian Journal of Primary Health, 14(3), 43–47.CrossRef
32.
Craig, C. L., Marshall, A. L., Sjöström, M., Bauman, A. E., Booth, M. L., Ainsworth, B. E., et al. (2003). International physical activity questionnaire: 12-country reliability and validity. Medicine and Science in Sports and Exercise, 35(8), 1381–1395.PubMedCrossRef
33.
Vickrey, B. G., Hays, R. D., Harooni, R., et al. (1995). A health-related quality of life measure for multiple sclerosis. Quality of Life Research, 4, 187–206.PubMedCrossRef
34.
Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21, 271–292.PubMedCrossRef
35.
Ferreira, L. N., Ferreira, P. L., Pereira, L. N., et al. (2013). Exploring the consistency of the SF-6D. Value Health, 16, 1023–1031.PubMedCrossRef
36.
Richardson, J., Khan, M. A., Iezzi, A., et al. (2015). Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments. Medical Decision Making, 35, 276–291.PubMedCrossRef
37.
Richardson, J., Iezzi, A., & Khan, M. A. (2015). Why do multi-attribute utility instruments produce different utilities: The relative importance of the descriptive systems, scale and ‘micro-utility’ effects. Quality of Life Research, 24, 2045–2053.PubMedPubMedCentralCrossRef
38.
Box, G., & Cox, D. (1964). An analysis of transformations. Journal of the Royal Statistical Society, Series B, 26, 211–252.
39.
Kohn, C. G., Sidovar, M. F., Kaur, K., Zhu, Y., & Coleman, C. I.(2014) Estimating a minimal clinically important difference for the EuroQol 5-Dimension health status index in persons with multiple sclerosis. Health and Quality of Life Outcomes, 12(1):66.PubMedPubMedCentralCrossRef
40.
Abel, H., Kephart, G., Packer, T., & Warner, G. (2017). Discordance in utility measurement in persons with neurological conditions: A comparison of the SF-6D and the HUI3. Value Health, 20, 1157–1165.PubMedCrossRef
41.
Diaz-Cruz, C., Chua, A. S., Malik, M. T., et al. (2017). The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Multiple Sclerosis and Related Disorders, 17, 47–53.PubMedCrossRef
42.
Greb, E. (2012). Half of patients with MS do not take disease-modifying medication within four years of diagnosis. Neurology Reviews, 20, 5–5.
43.
Norman, R., Church, J., van den Berg, B., et al. (2013). Australian health-related quality of life population norms derived from the SF-6D. The Australian and New Zealand Journal of Public Health, 37, 17–23.PubMedCrossRef
44.
Obradovic, M., Lal, A., & Liedgens, H. (2013). Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain. Health and Quality of Life Outcomes, 11, 110.PubMedPubMedCentralCrossRef
45.
Learmonth, Y. C., Motl, R. W., Sandroff, B. M., et al. (2013). Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurology, 13, 37.PubMedPubMedCentralCrossRef
Metagegevens
Titel
SF-6D health state utilities for lifestyle, sociodemographic and clinical characteristics of a large international cohort of people with multiple sclerosis
Auteurs
Julie A. Campbell
George A. Jelinek
Tracey J. Weiland
Nupur Nag
Sandra L. Neate
Andrew J. Palmer
Brendan Mulhern
Alysha De Livera
Steve Simpson-Yap
Publicatiedatum
01-06-2020
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2020
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-020-02505-6

Andere artikelen Uitgave 9/2020

Quality of Life Research 9/2020 Naar de uitgave

OriginalPaper

Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study

OriginalPaper

Humour and laughing in patients with prolonged incurable cancer: an ethnographic study in a comprehensive cancer centre

OriginalPaper

Better sleep, better life? How sleep quality influences children’s life satisfaction

OriginalPaper

Does the EQ-5D usual activities dimension measure what it intends to measure? The relative importance of work, study, housework, family or leisure activities

OriginalPaper

EORTC QLU-C10D value sets for Austria, Italy, and Poland

OriginalPaper

Health-related quality of life and its influencing factors in Chinese with knee osteoarthritis